

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/609,176
				Filing Date	June 27, 2003
				First Named Inventor	Thomas J. Guttuso, Jr.
				Art Unit	1617
				Examiner Name	S.A. Jiang
Sheet	1	of	4	Attorney Docket Number	176/60807 (6-11406-955)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
SG	1	US-5,344,830	09-06-1994	Mills et al.	
	2	US-5,554,627	09-10-1996	Lewis et al.	
	3	US-5,554,641	09-10-1996	Horwell et al.	
	4	US-5,563,161	10-08-1996	Huscroft et al.	
	5	US-5,594,022	01-14-1997	Horwell et al.	
	6	US-5,607,936	03-04-1997	Chiang et al.	
	7	US-5,610,145	03-11-1997	Horwell et al.	
	8	US-5,610,165	03-11-1997	MacCoss et al.	
	9	US-5,612,336	03-18-1997	Lewis et al.	
	10	US-5,624,947	04-29-1997	Keown et al.	
	11	US-5,627,211	05-06-1997	Teall et al.	
	12	US-5,633,266	05-27-1997	Baker et al.	
	13	US-5,635,509	06-03-1997	Jacobs et al.	
	14	US-5,633,281	05-27-1997	Teall et al.	
	15	US-5,654,316	08-05-1997	Carruthers et al.	
	16	US-5,663,352	09-02-1997	MacLeod et al.	
	17	US-5,665,883	09-09-1997	Baker et al.	
	18	US-5,688,960	11-18-1997	Shankar	
	19	US-5,969,123	12-09-1997	Dollinger et al.	
	20	US-5,696,267	12-09-1997	Reichard et al.	
	21	US-5,698,710	12-16-1997	Sisto et al.	
	22	US-5,708,006	01-13-1998	Dollinger et al.	
	23	US-5,719,156	02-17-1998	Shue et al.	
	24	US-5,731,309	03-24-1998	Bernstein et al.	
	25	US-5,760,018	06-02-1998	Baker et al.	
	26	US-5,760,248	06-02-1998	Sisto et al.	
	27	US-5,846,965	12-08-1998	MacKenzie et al.	
	28	US-5,849,795	12-15-1998	Sisto et al.	
	29	US-5,892,039	04-06-1999	Shue et al.	
	30	US-5,919,803	07-06-1999	Giblin et al.	
↓	31	US-5,922,744	07-13-1999	Harrison et al.	
	32	US-5,935,972	08-10-1999	Naylor et al.	
SG	33	US-5,945,428	08-31-1999	Shih et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)				

Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [222.uspto.gov](http://222.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/609,176
				Filing Date	June 27, 2003
				First Named Inventor	Thomas J. Guttuso, Jr.
				Group Art Unit	1617
				Examiner Name	S.A. Jiang
Sheet	3	of	4	Attorney Docket Number	176/60807 (6-11406-955)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
SG	50	Wallace et al., <u>Org. Lett.</u> 3(5):671-674 (2001)	
	51	Reichard et al., <u>Bioorg. Med. Chem. Lett.</u> 10(20):2329-2332 (2000)	
	52	Liu et al., <u>J. Med. Chem.</u> 43(21):3827-3831 (2000)	
	53	Nishi et al., <u>Bioorg. Med. Chem. Lett.</u> 10(15):1665-668 (2000)	
	54	Rosen et al., <u>Bioorg. Med. Chem. Lett.</u> 8(3):281-284 (1998)	
	55	Caliendo et al., <u>Farmaco</u> 52(10):589-593 (1997)	
	56	Kubota et al., <u>Chem. Pharm. Bull. (Tokyo)</u> 46(2):351-354 (1998)	
	57	Hirschmann et al., <u>J. Med. Chem.</u> 39(13):2441-2448 (1996)	
	58	Caliendo et al., <u>Farmaco</u> 50(11):755-759 (1995)	
	59	Karagiannis et al., <u>Int. J. Pept. Protein Res.</u> 42(6):565-569 (1993)	
	60	Rosen et al., <u>J. Med. Chem.</u> 36(21):3197-3201 (1993)	
SG	61	Caliendo et al., <u>Farmaco</u> 48(10):1359-1378 (1993)	

Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006
--------------------	------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/609,176
				Filing Date	June 27, 2003
				First Named Inventor	Thomas J. Guttuso, Jr.
				Group Art Unit	1617
				Examiner Name	S.A. Jiang
Sheet	4	of	4	Attorney Docket Number	176/60807 (6-11406-955)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SG	62	Manolopoulou et al., <u>Int. J. Pept. Protein Res.</u> 41(4):411-414 (1993)	
SG	63	Lawrence et al., <u>J. Med. Chem.</u> 35(7):1273-1279 (1992)	
SG	64	Aitken et al., <u>Bioorg. Med. Chem. Lett.</u> 11(5):659-661 (2001)	
SG	65	Elling et al., <u>Biochemistry</u> 39(4):667-675 (2000)	
SG	66	Bryans et al., "3-Substituted GABA Analogs with Central Nervous System Activity: A Review," <i>John Wiley &amp; Sons, Inc.</i> 29:149-177 (1999)	
SG	67	Guttuso, Jr., M.D., Thomas, "Gabapentin's Effects on Hot Flashes and Hypothermia," <i>American Academy of Neurology</i> 54:2161-2163 (2000)	
SG	68	Hardman et al., "Goodman & Gilman's The Pharmacological Basis of Therapeutics" (9 <sup>th</sup> ed, 1996) page 51 and 57-58	

Examiner Signature	/Shirley Gembah/	Date Considered	08/24/2006
--------------------	------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB-08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A-PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/609,176		
		Filing Date	June 27, 2003		
		First Named Inventor	Thomas J. Guttuso, Jr.		
		Art Unit	1617		
		Examiner Name	S.A. Jiang		
Sheet	1	of	1	Attorney Docket Number	176/60807 (6-11406-955)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>7</sup>
SG	1	Fisher et al., "Tachykinin Receptors Mediating Contractions of Oestrogen-Primed Rat Uterus: Classification Using Non-Peptide Antagonists," <i>Clinical and Experimental Pharmacology and Physiology</i> 26:729-735 (1999)	
SG	2	Moodley et al., "NK <sub>2</sub> Receptors Mediate Tachykinin-Induced Contractions of Rat Uterus During the Oestrous Cycle," <i>European Journal of Pharmacology</i> 376:53-60 (1999)	

Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449)	ATTY. DOCKET NO.		SERIAL NO.
	176/60807 (6-11405-955)		CON of 09/879,390
	APPLICANT		
	Thomas J. Guttuso, Jr.		
	FILING DATE		GROUP ART UNIT
	Herewith		

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
SG	1	5,744,156	4-23-98	De Lacharriere et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
SG	2	WO 99/09987	03/04/99	WIPO			
SG	3	WO 98/43639	10/08/98	WIPO			
SG	4	WO 96/24353	08/15/96	WIPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SG	5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging Therapies," <u>Current Opinion in Chemical Biology</u> 4:412-419 (2000)
SG	6	Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic Approaches," <u>Indian Journal of Pharmacology</u> 32:256-268 (2000)
SG	7	Von Sprecher et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis," <u>Idrugs</u> 1(1):73-91 (1998)
SG	8	Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger Ribonucleic Acids in the Hypothalamus of Postmenopausal Women," <u>Endocrinology</u> 128(5):2239-2247 (1991)
SG	9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion," <u>Science</u> 205:823-825 (1979)
SG	10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their Use as a Tumor Marker and Possible Role in the Carcinoid Flush," <u>Journal of Clinical Endocrinology and Metabolism</u> 63(3):605-612 (1986)
SG	11	Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush," <u>Scand. J. Gastroenterol.</u> 22: 97-105 (1986)
SG	12	Öberg et al., "The Effects of Octreotide on Basal and Stimulated Hormone Levels in Patients with Carcinoid Syndrome," <u>Journal of Clinical Endocrinology and Metabolism</u> 68(4):796-800 (1989)
EXAMINER		DATE CONSIDERED
/Shirley Gembeh/		08/24/2006
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449)	ATTY. DOCKET NO.  176/60807 (6-11405-955)	SERIAL NO.  CON of 09/879,390
	APPLICANT  Thomas J. Guttuso, Jr.	
	FILING DATE  Herewith	GROUP ART UNIT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

SG		13	Balks et al., "Effect of a Long-Acting Somatostatin Analogue (Octreotide) on Circulating Tachykinins and the Pentagastrin-Induced Carcinoid Flush," <u>Eur. J. Clin. Pharmacol.</u> 36:133-137 (1989)				
SG		14	Schaffalitzky de Muckadell et al., "Flushing and Plasma Substance P Concentration During Infusion of Synthetic Substance P in Normal Man," <u>Scand. J. Gastroenterol.</u> 21: 498-502 (1985)				
EXAMINER			DATE CONSIDERED				
/Shirley Gembeh/			08/24/2006				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							